Targeting PRMT5 in MTAP-deleted cancers
Official title: The function of the PRMT5 methylosome in MTAP deleted cancers
Funded at Broad Institute, INC. · NIH-11417989 · Data updated 2026-11-12
A research project tests a new approach to treat cancers that often lose MTAP, by using PRMT5 inhibitors to selectively kill cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | July 1, 2019 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $453,369 |
| NIH project number | 5R01CA233626-07 |
| Project ID | NIH-11417989 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with MTAP/CDKN2A-deleted pancreatic, esophageal, or lung cancers may benefit from future therapies guided by this work.
✕Less likely to help
This research is preclinical and may not directly impact patients in the near term.
What this research studies
This project builds on findings that MTAP-deleted cancers become highly dependent on PRMT5. It aims to understand what makes cancer cells sensitive or resistant to MTAC-P5i therapies using advanced CRISPR screening and model systems. The study will explore how tumor cells interact with their environment to influence treatment response and identify combination strategies to improve effectiveness. Results could guide future clinical trials for patients with pancreatic, esophageal, or lung cancers carrying MTAP/CDKN2A deletions.
Why it matters
Potential benefit: If successful, the research could inform better, targeted treatment options for MTAP-deleted cancers and help design combinations that overcome resistance.
How similar studies have gone: Early clinical data show MTAC-P5i therapies can elicit tumor responses with tolerable safety, supporting further investigation.
Where this research is happening
-
Broad Institute, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Sellers, William R — Broad Institute, INC.
- Study coordinator: Sellers, William R
Related research
Other NIH-funded projects on the same topics.
-
Broad-Color: A Center to Accelerate All of Us Genomics
A national effort to speed up personalized medicine by expanding genomic data and clinical insight for All of Us participants.
-
Common Fund data knowledge center to make big data insights easy to use
A project to make NIH Common Fund datasets easy to find, understand, and use for researchers by turning them into trusted, clearly explained knowledge that supports big data discoveries.
-
Massive-scale genomic risk assessment to inform precision medicine for diabetes
A large study aims to map how genetic differences influence different forms of diabetes to guide personalized care.
-
Massive-scale genetic risk profiling to guide personalized diabetes care
A large NIH-funded project will study how many diabetes-related genetic variants influence risk across diverse populations to help tailor prevention and treatment.
-
Asian Bipolar Genetics Network study
This project studies the genetics of bipolar disorder in East and South Asian people to better understand risk factors and how they may affect diagnosis and care.
-
Broad-Color: A Genomic Center to Accelerate All of Us for Better Health
A national genomic resource project will expand and speed up how researchers use genetic data from All of Us participants to improve understanding, diagnosis, and treatment of human diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.